Is HIMS a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Recurring subscription model, with revenue (ttm) at ~$2.37 billion. The bear case rests on the GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026. Analysts covering it are spread from $21.00 to $40.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $21.00, -24.4% from the $27.78 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Recurring subscription model. Hims is built on auto-refilling monthly subscriptions rather than one-time sales, which produces predictable, compounding revenue as the base grows. The most optimistic analyst target on HIMS is $40.00, +44.0% from the $27.78 price. That figure is only reachable if this thesis works close to its best case.

The GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026. Competition is intense and well funded, including Ro, LifeMD, Teladoc, and numerous smaller GLP-1 telehealth providers, which can raise customer-acquisition costs. Growth decelerated to roughly 4 percent year over year in the first quarter of 2026 even as the valuation stayed rich relative to current profitability, so any further slowdown or margin erosion could weigh on the stock. The company also carries dependence on a few high-demand categories and on continued heavy marketing spend. The most pessimistic published target is $21.00, -24.4% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Hims & Hers Health operates a direct-to-consumer telehealth platform that connects users with licensed providers and ships personalized prescription and over-the-counter products o

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Recurring subscription model) stalling in the reported numbers rather than in the narrative, the risk above (the GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not advice. The bull case is a growing subscription base, category expansion, and 2030 revenue targets. The bear case is decelerating growth near 4 percent, gross margins compressed to about 65 percent, GLP-1 regulatory risk, and a rich valuation versus current profits. Weigh both against your own plan.

Hims & Hers runs a direct-to-consumer telehealth platform. Users complete an online consultation, connect with licensed providers, and receive personalized prescription and wellness products shipped on a recurring subscription. Categories include sexual health, hair loss and dermatology, mental health, women's health, and weight management. Most revenue comes from auto-refilling monthly subscriptions rather than one-time purchases.

No. Hims & Hers does not pay a dividend. Like most growth-stage companies, it reinvests cash into marketing, category expansion, vertical integration such as pharmacies and manufacturing, and other initiatives. Any return from owning the shares would come from price changes rather than dividend income. Check a current quote if you need to confirm dividend status before investing.